Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Kebapcilar L., Kebapcilar A. G., Bilgir O., Taner C. E., Bozkaya G., Yildiz Y., ...Daha Fazla

GYNECOLOGICAL ENDOCRINOLOGY, cilt.27, sa.2, ss.91-95, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3109/09513590.2010.491164
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.91-95
  • Anahtar Kelimeler: sCD40L, metformin, ethinyl oestradiol plus cyproterone acetate, PCOS, POLYCYSTIC-OVARY-SYNDROME, ACTIVATABLE FIBRINOLYSIS INHIBITOR, CARDIOVASCULAR RISK-FACTORS, FACTOR-KAPPA-B, POSTMENOPAUSAL WOMEN, NUCLEAR-FACTOR, ENDOTHELIAL-CELLS, CD40 LIGAND, DISEASE, ATHEROSCLEROSIS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Methods. Total of 60 patients with PCOS was studied to evaluate and compare with a non-PCOS group consisting of 30 subjects. A low-dose oral contraceptive containing ethinyl oestradiol-cyproterone acetate (EE/CA) and metformin (M; 850 mg metformin twice a day) were given for three cycles. Plasma sCD40L was measured before and after the treatment of 3 months.